• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

17.44 +0.16 (+0.93%)
Delayed Quote Updated: 4:00 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,176,095
Open 17.51
Bid (Size) 17.28 (500)
Ask (Size) 18.20 (400)
Prev. Close 17.28
Today's Range 17.28 - 18.01
52wk Range 5.950 - 21.27
Shares Outstanding 121,613,181
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
November 02, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
October 28, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 18.0% below 52-week high
17.44
5.9552W Low 21.2752W High
1 Week 13.7% below 1-week high
17.241W Low 20.201W High

Relay Therapeutics, Inc. - Common Stock (RLAY) traded between $5.95 and $21.27 over the past 52 weeks and last traded at $17.44, 18.0% below its 52-week high. Over the past week it ranged between $17.24 and $20.20.

Past 12 Months
-7.4%
-10.1%
-7.1%
+33.2%
+113.2%
+151.3%
1W -$1.40
1M -$1.95
3M -$1.34
6M +$4.35
YTD +$9.26
1Y +$10.50

RLAY was +151.3% over the past year, +33.2% over six months, +113.2% year to date, -7.4% in the last week.

12 Months vs Market
RLAY
+151.3%
DIA
+9.2%
SPY
+10.4%
QQQ
+8.4%
IWM
+14.0%

Over the past 12 months RLAY returned +151.3% versus DIA (Dow) +9.2%, SPY (S&P 500) +10.4%, QQQ (Nasdaq 100) +8.4% and IWM (Russell 2000) +14.0%.

Volume & Liquidity 1.15× 3-mo avg
Today 3,176,095 3-mo avg 2.8M
1W
2.7M
1M
2.5M
3M
2.8M
6M
3.4M
YTD
3.1M
1Y
3.0M

RLAY most recently traded 3,176,095 shares against a 3-month average daily volume of 2.8M.

More News

Read More
News headline image
Relay Therapeutics CFO Sells 17,717 Shares for $350,000 ↗
September 02, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
September 01, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics (NASDAQ:RLAY) Reports Q2 2026 Revenue Miss as Loss Widens Slightly ↗
August 06, 2026
Via Chartmill
Relay Therapeutics (NASDAQ:RLAY) Beats Q1 Estimates but Slips on Wider Loss and Lack of Guidance ↗
May 05, 2026
Via Chartmill
News headline image
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
August 06, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
July 30, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year ↗
June 29, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
May 27, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Is Relay Therapeutics a Buy After Promising Trial Results? ↗
May 22, 2026
Via The Motley Fool
News headline image
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
May 20, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Relay Therapeutics Stock Popped on Wednesday ↗
May 20, 2026
Via The Motley Fool
News headline image
Relay Therapeutics Announces Proposed Public Offering of Common Stock
May 19, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
May 19, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million ↗
May 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Energy Vault Stock Has Surged 500%. One Major Holder Just Sold 3 Million Shares ↗
May 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
May 05, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
April 29, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
April 27, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
April 02, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
March 19, 2026
Via The Motley Fool
News headline image
Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
March 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
March 16, 2026
From Relay Therapeutics, Inc.
Via GlobeNewswire
News headline image
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗
February 27, 2026
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Relay Therapeutics, Inc. - Common Stock publicly traded?
Yes, Relay Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Relay Therapeutics, Inc. - Common Stock trade on?
Relay Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Relay Therapeutics, Inc. - Common Stock?
The ticker symbol for Relay Therapeutics, Inc. - Common Stock is RLAY on the Nasdaq Stock Market
What is the current price of Relay Therapeutics, Inc. - Common Stock?
The current price of Relay Therapeutics, Inc. - Common Stock is 17.44
When was Relay Therapeutics, Inc. - Common Stock last traded?
The last trade of Relay Therapeutics, Inc. - Common Stock was at 11/03/26 04:00 PM ET
What is the market capitalization of Relay Therapeutics, Inc. - Common Stock?
The market capitalization of Relay Therapeutics, Inc. - Common Stock is 2.12B
How many shares of Relay Therapeutics, Inc. - Common Stock are outstanding?
Relay Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap